Search results
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
Reuters via Yahoo News· 7 days agoThe drug candidate, mitapivat, significantly reduced the need for blood transfusion in adult patients with transfusion-dependent alpha—or beta-thalassemia. Thalassemia ...
Stem Cells Fast Facts
KEYT 3 Santa Barbara· 4 days agoScientists believe that stem cell research can be used to treat medical conditions including Parkinson’s disease, spinal cord injury, stroke, burns,...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 2 days agoVertex and partner Crispr Therapeutics gained Food and Drug Administration approval for a...
The Good News You Might Have Missed, By Angus Hervey | DailyGood
DailyGood· 3 days agoEverywhere we look, there are reports of decline. Well, your answer to that question probably...
Cathie Wood Invests In 2 Biotechnology Stocks – Are They Worth Buying?
Benzinga via Yahoo Finance· 2 days agoWith her ARK Innovation ETF (ARKK: NYSE Arca), Cathie Wood makes large wagers on biotech businesses...
These Biotech Stocks Hit New Highs, Did You Reap The Rewards?
RTT News· 3 days agoThe following compilation represents a selection of stocks featured on our website that reached new 52-week high levels during the current week. Protagonist is a clinical-stage biopharmaceutical ...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You? | The Motley Fool
The Motley Fool· 6 days agoVia her ARK Innovation ETF (ARKK 1.47%), portfolio manager Cathie Wood makes a lot of biotech bets,...
FLiRTing with a COVID summer surge? What to know about the newest family of Omicron subvariants
Fortune· 4 days ago“This is not a surprise; this is always in the cards,” Edwin Michael, PhD, an epidemiologist at the University of South Florida College of Public Health, tells Fortune. “The mutations will keep ...
Agios Pharmaceuticals Shares Rise 16% After Positive Trial Data for Mitapivat
Market Watch· 6 days agoAgios Pharmaceuticals shares were up 16% to $42 after the company said its global Phase 3 study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday -...
Benzinga· 6 days agoOlema Pharmaceuticals, Inc . OLMA gained 15.5% to $11.18. Agios Pharmaceuticals, Inc . AGIO gained 13.7% to $41.30 as the company reported Phase 3 results for mitapivat in reducing ...